Placeholder canvas

Covaxin Effectively Neutralises Both Alpha, Delta Variants Of Covid-19: US’ Top Health Institute

Date:

The National Institute of Health (NIH) in the United States has found that Bharat Biotech’s COVAXIN vaccine generates antibodies that effectively neutralize both Alpha and Delta variants of COVID-19. The top health research institute said that an adjuvant developed with funding from the NIH has contributed to the success of the “highly efficacious” COVAXIN COVID-19 vaccine, which roughly 25 million people have received to date in India and elsewhere.

“Results from two studies of blood serum from people who had received COVAXIN suggest that the vaccine generates antibodies that effectively neutralize the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the United Kingdom and India, respectively,” NIH said in a statement.

The adjuvant used in COVAXIN, Alhydroxiquim-II, was discovered and tested in the laboratory by the biotech company ViroVax LLC of Lawrence, Kansas with support exclusively from the NIAID Adjuvant Development Program, NIH said.

Also Read : G20: Matera Declaration Reflects Indian Concern For Farmer Welfare, Agri-Diversity, Says EAM Jaishankar

The adjuvant comprises a small molecule attached in a unique way to Alhydrogel, a substance frequently called alum that is the most commonly used adjuvant in vaccines for people. “Ending a global pandemic requires a global response,” said Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), a part of NIH. “I am pleased that a novel vaccine adjuvant developed in the United States with NIAID support is part of an efficacious COVID-19 vaccine available to people in India.”

COVAXIN comprises a disabled form of SARS-CoV-2 that cannot replicate but still stimulates the immune system to make antibodies against the virus. Published results from a Phase 2 trial of the vaccine indicate that it is safe and well-tolerated.

Unpublished interim results from the Phase 3 trial indicate that the vaccine has 78 per cent efficacy against symptomatic disease, 100 per cent efficacy against severe COVID-19, including hospitalization, and 70 per cent efficacy against asymptomatic infection with SARS-CoV-2, the virus that causes COVID-19.

(With ANI Inputs)

Click here for Latest News updates and viral videos on our AI-powered smart news

For viral videos and Latest trends subscribe to NewsMobile YouTube Channel and Follow us on Instagram

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Subscribe

Popular

More like this
Related

Biden Administration Approves $60Million Aid For Baltimore Bridge Collapse

The Federal Administration in a statement on Thursday said that it has provided the quick-release funds to rebuild the collapsed bridge within hours of receiving a request from Maryland Department Of Transportation

Fact Check: Lok Sabha Polls Will Be Held Using EVMs; Don’t Fall For False Claim

Ahead of the Lok Sabha polls, a newspaper cutout...

Four Killed, Five Wounded In Stabbing Incident In North Illinois

Redd mentioned that not all of the victims had stab wounds and none of them were shot. She added by saying that they have a suspect in custody

Hope Everyone’s Rights Are Protected: UN On Kejriwal’s Arrest

Delhi CM Kejriwal was arrested by the ED(Enforcement Directorate) on March 21 in the Delhi liquor policy case, days ahead of the Lok Sabha polls